Steroidogenesis in the NCI-H295 Cell Line Model is Strongly Affected By Culture Conditions and Substrain

Abstract

Context NCI-H295 cells are the most widely used model for adrenal steroidogenesis and adrenocortical carcinoma and have been used for decades in laboratories worldwide. However, reported steroidogenic properties differ considerably.

Objective To evaluate heterogeneity of steroidogenesis among NCI-H295 cell strains, clarify the influence of culture media and test response to inhibitors of steroidogenesis by using liquid chromatography tandem mass spectrometry (LC-MS/MS).

Methods NCI-H295 cells were obtained from two cell banks and cultivated in different media. An LC-MS/MS-based panel analysis of thirteen steroids was adapted for cell culture supernatant. Cells were treated with metyrapone, abiraterone and mitotane.

Results Mineralocorticoid synthesis was strongly affected by passaging as reflected by reduction of aldosterone secretion from 0.158±0.006 to 0.017±0.001 µg/10⁶ cells (p<0.05). Relevant differences were also found for cells from two vendors in terms of aldosterone secretion (0.180±0.001 vs. 0.09±0.002 µg/10⁶ cells, p<0.05). Selection of medium strongly impacted on cortisol secretion with>4-fold difference (40.6±5.5 vs. 182.1±23 µg/10⁶ cells) and reflected differential activation of the glucocorticoid pathway. Exposure to abiraterone, metyrapone and mitotane resulted in characteristic steroidogenic profiles consistent with known mechanism of drug action with considerable differences in metabolites upstream of the blocked enzyme.

Conclusion We demonstrate that steroid hormone secretion in NCI-H295 cells is strongly affected by the individual strain, passage and growing conditions. These factors should be taken into account in the evaluation of experiments analyzing steroid parameters directly or as surrogate parameters of cell viability.

Key words

Steroid hormones - glucocorticoids - androgens - adrenocortical carcinoma - cell culture

Publication History

Received: 16 January 2020
Received: 21 August 2019

Accepted: 23 January 2020

Article published online:
29 April 2020

• References

• 1 Golden SH, Robinson KA, Saldanha I. et al. Clinical review: Prevalence and incidence of endocrine and metabolic disorders in the United States: A comprehensive review. J Clin Endocrinol Metab 2009; 94: 1853-1878.
• 2 Kerkhofs TM, Verhoeven RH, Van der Zwan JM. et al. Adrenocortical carcinoma: A population-based study on incidence and survival in the Netherlands since 1993. Eur J Cancer 2013;
• 3 Fassnacht M, Kroiss M, Allolio B. Update in adrenocortical carcinoma. J Clin Endocrinol Metab 2013; 98: 4551-4564. doi: 10.1210/jc.2013-3020
• 4 Else T, Kim AC, Sabolch A. et al. Adrenocortical carcinoma. Endocrine reviews 2014; 35: 282-326.
• 5 Libe R, Borget I, Ronchi CL. et al. Prognostic factors in stage III-IV adrenocortical carcinomas (ACC): An European Network for the Study of Adrenal Tumor (ENSAT) study. Annals of oncology: Official journal of the European Society for Medical Oncology / ESMO 2015; 26: 2119-2125.
• 6 Poli G, Cantini G, Armignacco R. et al. Metformin as a new anti-cancer drug in adrenocortical carcinoma. Oncotarget 2016; 7: 49636-49648
• 7 LaPensee CR, Mann JE, Rainey WE. et al. ATR-101, a Selective and Potent Inhibitor of Acyl-CoA Acyltransferase 1, Induces Apoptosis in H295R Adrenocortical Cells and in the Adrenal Cortex of Dogs. Endocrinology 2016; 157: 1775-1788.
• 8 Kroiss M, Sbiera S, Kendl S. et al. Drug Synergism of Proteasome Inhibitors and Mitotane by Complementary Activation of ER Stress in Adrenocortical Carcinoma Cells. Horm Cancer 2016; 7 (5-6) 345-355.
• 9 Sbiera S, Leich E, Liebisch G. et al. Mitotane Inhibits Sterol-O-Acyl Transferase 1 Triggering Lipid-Mediated Endoplasmic Reticulum Stress and Apoptosis in Adrenocortical Carcinoma Cells. Endocrinology 2015; 156: 3895-3908
• 10 Germano A, Rapa I, Volante M. et al. Cytotoxic activity of gemcitabine, alone or in combination with mitotane, in adrenocortical carcinoma cell lines. Molecular and cellular endocrinology 2014; 382: 1-7.
• 11 Mariniello B, Rosato A, Zuccolotto G. et al. Combination of sorafenib and everolimus impacts therapeutically on adrenocortical tumor models. Endocr Relat Cancer 2012; 19: 527-539
• 12 Lafont J, Laurent M, Thibout H. et al. The expression of novH in adrenocortical cells is down-regulated by TGFbeta 1 through c-Jun in a Smad-independent manner. The Journal of biological chemistry 2002; 277: 41220-41229.
• 13 Brenner T, O'Shaughnessy KM. Both TASK-3 and TREK-1 two-pore loop K channels are expressed in H295R cells and modulate their membrane potential and aldosterone secretion. American journal of physiology. Endocrinology and metabolism 2008; 295: E1480-E1486. doi: 10.1152/ajpendo.90652.2008
• 14 Ma Y, Han J, Guo Y. et al. Disruption of endocrine function in in vitro H295R cell-based and in in vivo assay in zebrafish by 2,4-dichlorophenol. Aquat Toxicol 2012; 106-107: 173-181
• 15 Karmaus AL, Toole CM, Filer DL. et al. High-Throughput Screening of Chemical Effects on Steroidogenesis Using H295R Human Adrenocortical Carcinoma Cells. Toxicological sciences: An official journal of the Society of Toxicology 2016; 150: 323-332
• 16 Gracia T, Hilscherova K, Jones PD. et al. Modulation of steroidogenic gene expression and hormone production of H295R cells by pharmaceuticals and other environmentally active compounds. Toxicology and applied pharmacology 2007; 225: 142-153.
• 17 Canton RF, Sanderson JT, Nijmeijer S. et al. In vitro effects of brominated flame retardants and metabolites on CYP17 catalytic activity: A novel mechanism of action?. Toxicology and applied pharmacology 2006; 216: 274-281.
• 18 Havelock JC, Auchus RJ, Rainey WE. The rise in adrenal androgen biosynthesis: Adrenarche. Semin Reprod Med 2004; 22: 337-347. doi: 10.1055/s-2004-861550
• 19 Hantel C, Shapiro I, Poli G. et al. Targeting heterogeneity of adrenocortical carcinoma: Evaluation and extension of preclinical tumor models to improve clinical translation. Oncotarget 2016; 7: 79292-79304.
• 20 Kiseljak-Vassiliades K, Zhang Y, Bagby SM. et al. Development of new preclinical models to advance adrenocortical carcinoma research. Endocr Relat Cancer 2018; 25: 437-451
• 21 Gazdar AF, Oie HK, Shackleton CH. et al. Establishment and characterization of a human adrenocortical carcinoma cell line that expresses multiple pathways of steroid biosynthesis. Cancer Res 1990; 50: 5488-5496
• 22 Wang T, Rainey WE. Human adrenocortical carcinoma cell lines. Mol Cell Endocrinol 2012; 351: 58-65. doi: 10.1016/j.mce.2011.08.041
• 23 Parmar J, Key RE, Rainey WE. Development of an adrenocorticotropin-responsive human adrenocortical carcinoma cell line. J Clin Endocrinol Metab 2008; 93: 4542-4546 doi: 10.1210/jc.2008-0903
• 24 Rainey WE, Bird IM, Mason JI. The NCI-H295 cell line: a pluripotent model for human adrenocortical studies. Mol Cell Endocrinol 1994; 100: 45-50
• 25 Lichtenauer UD, Shapiro I, Osswald A. et al. Characterization of NCI-H295R cells as an in vitro model of hyperaldosteronism. Horm Metab Res 2013; 45: 124-129
• 26 Samandari E, Kempna P, Nuoffer JM. et al. Human adrenal corticocarcinoma NCI-H295R cells produce more androgens than NCI-H295A cells and differ in 3beta-hydroxysteroid dehydrogenase type 2 and 17,20 lyase activities. J Endocrinol 2007; 195: 459-472
• 27 Bird IM, Hanley NA, Word RA. et al. Human NCI-H295 adrenocortical carcinoma cells: a model for angiotensin-II-responsive aldosterone secretion. Endocrinology 1993; 133: 1555-1561.
• 28 Bird IM, Mason JI, Oka K. et al. Angiotensin-II stimulates an increase in cAMP and expression of 17 alpha-hydroxylase cytochrome P450 in fetal bovine adrenocortical cells. Endocrinology 1993; 132: 932-934.
• 29 Rainey WE, Bird IM, Sawetawan C. et al. Regulation of human adrenal carcinoma cell (NCI-H295) production of C19 steroids. J Clin Endocrinol Metab 1993; 77: 731-737
• 30 McAllister JM, Hornsby PJ. Dual regulation of 3 beta-hydroxysteroid dehydrogenase, 17 alpha-hydroxylase, and dehydroepiandrosterone sulfotransferase by adenosine 3',5'-monophosphate and activators of protein kinase C in cultured human adrenocortical cells. Endocrinology 1988; 122: 2012-2018. doi: 10.1210/endo-122-5-2012
• 31 Ben-David U, Siranosian B, Ha G. et al. Genetic and transcriptional evolution alters cancer cell line drug response. Nature 2018; 560 (7718) 325-330.
• 32 Wang T, Rowland JG, Parmar J. et al. Comparison of aldosterone production among human adrenocortical cell lines. Horm Metab Res 2012; 44: 245-250.
• 33 Hornsby PJ, Yang LQ. A model for phenotypic switching in adrenocortical cells senescing in culture. Mech Ageing Dev 1991; 58: 1-12
• 34 Hilscherova K, Jones PD, Gracia T. et al. Assessment of the effects of chemicals on the expression of ten steroidogenic genes in the H295R cell line using real-time PCR. Toxicol Sci 2004; 81: 78-89
• 35 Pia A, Vignani F, Attard G. et al. Strategies for managing ACTH dependent mineralocorticoid excess induced by abiraterone. Cancer Treat Rev 2013; 39: 966-973.
• 36 Sanders K, de Wit WL, Mol JA. et al. Abiraterone Acetate for Cushing's Syndrome: Study in a Canine Primary Adrenocortical Cell Culture Model. Endocrinology. 2018
• 37 Germano A, Saba L, De Francia S. et al. CYP11B1 has no role in mitotane action and metabolism in adrenocortical carcinoma cells. PloS one 2018; 13: e0196931.
• 38 Krone N, Hughes BA, Lavery GG. et al. Gas chromatography/mass spectrometry (GC/MS) remains a pre-eminent discovery tool in clinical steroid investigations even in the era of fast liquid chromatography tandem mass spectrometry (LC/MS/MS). J Steroid Biochem Mol Biol 2010; 121 (3-5) 496-504.